Nanocarrier vaccines for SARS-CoV-2

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative t...

Descripción completa

Detalles Bibliográficos
Autores principales: Machhi, Jatin, Shahjin, Farah, Das, Srijanee, Patel, Milankumar, Abdelmoaty, Mai Mohamed, Cohen, Jacob D., Singh, Preet Amol, Baldi, Ashish, Bajwa, Neha, Kumar, Raj, Vora, Lalit K., Patel, Tapan A., Oleynikov, Maxim D., Soni, Dhruvkumar, Yeapuri, Pravin, Mukadam, Insiya, Chakraborty, Rajashree, Saksena, Caroline G., Herskovitz, Jonathan, Hasan, Mahmudul, Oupicky, David, Das, Suvarthi, Donnelly, Ryan F., Hettie, Kenneth S., Chang, Linda, Gendelman, Howard E., Kevadiya, Bhavesh D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794055/
https://www.ncbi.nlm.nih.gov/pubmed/33428995
http://dx.doi.org/10.1016/j.addr.2021.01.002
Descripción
Sumario:The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

Ejemplares similares